Observing Effects of Switching to Tildrakizumab in Adults with Moderate to Severe Plaque Psoriasis in Austria and Switzerland

What this Trial Is About

This research aims to evaluate the effects of switching from another biologic treatment to tildrakizumab in adults with moderate to severe plaque psoriasis. It focuses on patient-reported outcomes, psoriasis severity, quality of life before and after switching, and the reasons patients choose to change biologic therapies. The study is observational and takes place in real-world clinical settings. Participants prescribed tildrakizumab according to routine clinical practice will be observed for up to 28 weeks. The study does not involve assigning treatments but follows patients who switch to tildrakizumab as part of their care. Researchers will track changes in psoriasis severity and patient satisfaction with medication over this period. During the study, participants will complete questionnaires such as the Treatment Satisfaction Questionnaire for Medication-11 and the World Health Organisation Well-Being Index at the start and after 28 weeks. Psoriasis severity and quality of life will also be assessed at multiple time points using clinical scores and patient questionnaires. The study monitors participants health and treatment satisfaction throughout the observation period.

A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis